Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|June 20, 2019
Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian CancerThaïs Baert, Ann Vankerckhoven, Matteo Riva, et al.
Cells|February 5, 2020
Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot StudyAnn Vankerckhoven, Roxanne Wouters, Thomas Mathivet, et al.
British Journal of Cancer|April 4, 2026
Value of whole-body diffusion-weighted MRI for the prediction of surgical and clinical outcome after neoadjuvant chemotherapy in advanced ovarian cancerVincent Vandecaveye, Raphaëla C Dresen, Thaïs Baert, et al.
Gynecologic Oncology|May 13, 2018
Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patientsThaïs Baert, Joke Van Camp, Lisa Vanbrabant, et al.
Anticancer Research|October 30, 2016
The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian CancerEva Vindevogel, Thaïs Baert, Anaïs VAN Hoylandt, et al.
Cells|January 11, 2024
A Microfluidics Approach for Ovarian Cancer Immune Monitoring in an Outpatient SettingSarah Libbrecht, Ann Vankerckhoven, Koen de Wijs, et al.
Current Oncology Reports|January 29, 2020
Low-grade Serous Tumors: Are We Making Progress?Nina Pauly, Sarah Ehmann, Enzo Ricciardi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 7, 2024
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trialTine Ottenbourgs, Toon van Gorp, Frédéric Kridelka, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trialTine Ottenbourgs, Toon van Gorp, Frédéric Kridelka, et al.
Cancers|December 10, 2021
Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian CancerChristine De Bruyn, Jolien Ceusters, Chiara Landolfo, et al.
Pageof 4